Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
samedi, novembre 14
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Sanofi SA
SNY
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$48.37
-0.09
-0.19%
À la clôture: Nov 13, 4:00 PM EST
$47.99
-0.38
-0.79%
Après les heures: 7:22 PM EST
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Dividendes
Comparer
Options
Rapport sur les stocks
Sanofi Financials
Sanofi (SNY) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Regeneron Eyes One of Its Strongest Years Ever, Stock Jumps
Regeneron stock hits a 52-week high as earnings surge 70%, revenue jumps 36% and key drugs deliver record sales.
Vandana Singh
Dupixent Is Still Booming. Sanofi’s CEO Is Already Planning for Life Without It
Sanofi beats Q3 earnings consensus on Dupixent growth, raises 2026 guidance, and outlines long-term plans to handle upcoming patent expirations.
Vandana Singh
PRO
Sanofi Q3 Adj. EPS $2.04 Beats $1.63 Estimate, Sales $16.623B Beat $15.230B Estimate
Sanofi (NASDAQ:SNY) reported quarterly earnings of $2.04 per share which beat the analyst consensus estimate of $1.63 by 25.15 percent. This is a 22.16 percent increase over earnings of $1.67 per share from the same
Benzinga Newsdesk
PRO
Sanofi Q3 Dupixent Sales €5.7B, Up 34.8%; Vaccines Sales €3.2B, Down 6.6%
Benzinga Newsdesk
PRO
Sanofi Raises FY26 Guidance: Sees Sales Growth Low-Teens % At CER, Business EPS Growth Mid-Teens %
Benzinga Newsdesk
PRO
Sanofi Q3 Business EPS €3.55, Up 22%; Sales €14.44B, Up 16.2%, Up 14.3% At CER
Benzinga Newsdesk
